VEGF-C Antibody (MM0006-2E65): sc-101583
- VEGF-C Antibody (MM0006-2E65) is a mouse monoclonal IgG2, cited in 1 publications, provided at 100 µg/ml
- raised against recombinant VEGF-C of human origin
- recommended for detection of VEGF-C of human origin by WB, IP, IF and IHC(P); non cross-reactive with VEGF, VEGF-B or VEGF-D
- See VEGF-C (E-6): sc-374628 for VEGF-C antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for VEGF-C Antibody (MM0006-2E65). This work is in progress.
VEGF-C Antibody (MM0006-2E65) is a mouse monoclonal IgG2 antibody that detects vascular endothelial growth factor C (VEGF-C) in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. VEGF-C plays a crucial role in lymphangiogenesis, the formation of lymphatic vessels, which is essential for maintaining fluid homeostasis and immune responses in tissues. VEGF-C is primarily located in the extracellular space and is secreted by various cell types, including endothelial cells and fibroblasts. Proper localization of VEGF-C is vital, as VEGF-C interacts with specific receptors such as Flt-4, which mediates effects on lymphatic endothelial cells, promoting their proliferation and migration. Dysregulation of VEGF-C signaling has been implicated in several pathological conditions, including cancer metastasis and lymphedema, making VEGF-C a significant target for therapeutic interventions. Anti-VEGF-C antibody (MM0006-2E65) is an invaluable tool for researchers studying the mechanisms of angiogenesis and lymphangiogenesis, as well as their implications in disease progression.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
VEGF-C Antibody (MM0006-2E65) References:
- VEGF-C as a putative therapeutic target in cancer. | Michaelsen, SR., et al. 2019. Oncotarget. 10: 3988-3990. PMID: 31258839
- VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. | Song, E., et al. 2020. Nature. 577: 689-694. PMID: 31942068
- VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma. | Abe, I., et al. 2021. Histol Histopathol. 36: 645-652. PMID: 33734425
- VEGF-C/VEGFR-3 axis protects against pressure-overload induced cardiac dysfunction through regulation of lymphangiogenesis. | Lin, QY., et al. 2021. Clin Transl Med. 11: e374. PMID: 33783987
- VEGF-C/VEGFR-3 signalling in macrophages ameliorates acute lung injury. | Yamashita, M., et al. 2022. Eur Respir J. 59: PMID: 34446463
- Visfatin upregulates VEGF-C expression and lymphangiogenesis in esophageal cancer by activating MEK1/2-ERK and NF-κB signaling. | Huang, CL., et al. 2023. Aging (Albany NY). 15: 4774-4793. PMID: 37286356
- VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells. | Banerjee, K., et al. 2023. Cell Rep. 42: 113507. PMID: 38041815
- Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema. | Creff, J., et al. 2024. EMBO Mol Med. 16: 386-415. PMID: 38177539
- VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model. | Boisserand, LSB., et al. 2024. J Exp Med. 221: PMID: 38442272
- The Impact of VEGF-C-Induced Dural Lymphatic Vessel Growth on Ischemic Stroke Pathology. | Keuters, MH., et al. 2024. Transl Stroke Res.. PMID: 38822994
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VEGF-C Antibody (MM0006-2E65) | sc-101583 | 100 µg/ml | $322.00 |